cannabinoid receptor

(redirected from CB2 receptor)

cannabinoid receptor

THC receptor, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Resunab is designed to trigger the resolution of chronic inflammation by binding to and activating the CB2 receptor on immune cells (in effect, turning inflammation 'off').
(10) The CB2 receptor is also involved in reducing oxidative stress associated with cellular senescence, indicating the endocannabinoid system is involved in healthy aging.
Resunab is a novel synthetic oral drug that is a preferential agonist to the CB2 receptor expressed on activated immune cells.
MDA19 was designed to have a much stronger effect on the CB2 receptor than on the CB1 receptor.
It is a new, oral specialised pro-resolving mediator drug and it binds to the CB2 receptor on immune cells and triggers a process known as inflammatory resolution, in effect turning chronic inflammation off.
APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate the company is exploring for several potential indications, including chronic pain.
Beta-caryophyllene is one of the most abundant terpenoids found in the essential oil of cannabis that activates the CB2 receptor. However, it's not only found in cannabis -- beta-caryophyllene is also commonplace throughout the plant kingdom and found in many herbal essential oils, including clove, oregano, cinnamon, and black pepper.
The adaptogenic action of AnnonaSense CLR supports the endocannabinoid system (ECS) by activating the CB2 receptor. Inflammatory processes induced by the TRPV1 receptor, part of the skin's endovanilloid system (EVS), are strongly down regulated and a stable balance between the ECS and EVS is established.
In 1988, the first canabinnoid receptor was identified and isolated and named endocannabinoid receptor type 1 (CB1 receptor); a second canabinnoid receptor was discovered in 1993 and named endocannabinoid receptor type 2 (CB2 receptor) (MUNRO et al., 1993).
(NASDAQ: TRPX) has released positive results in its pre-clinical studies evaluating THX-160, a novel pharmaceutical CB2 Receptor agonist for the treatment of pain, the company said.
For the CB2 receptor, the optimal combination with the wild-type [beta]arr2 was found to be CB2-SmBiT LgBiT-[beta]arr2 (Fig.
In mice, peripheral administration of low doses of JZL184 was found to prevent the development of cisplatin-induced mechanical hyperalgesia in a CB1 receptor, but not CB2 receptor, dependent manner [26].